EASYWELL BIOMEDICALS (formerly Actherm, Inc.) is a global biopharmaceutical and medical device company dedicated to the development and commercialization of medical devices, drug substances, and pharmaceutical dosage forms. Headquartered in Hsinchu, Taiwan, the company has a cGMP medical device plant in Shenzhen, China and a cGMP pharmaceutical development and manufacturing facility in Cranbury, New Jersey, USA.

Incorporated in July 1998, EASYWELL BIOMEDICALS was initially focused on electronic monitoring devices that received CE marks and USFDA clearance. These devices include digital clinical thermometers, infrared ear thermometers, and Transcutaneous Electrical Nerve Stimulation (TENS) products for pain relief. In 2014, EASYWELL BIOMEDICALS became a fully integrated biopharmaceutical company after it acquired Magnifica, Inc., a US specialty pharmaceutical company focused on the development of drug substances and pharmaceutical dosage forms.

EASYWELL BIOMEDICALS’s pharmaceutical sector focuses on the development of generics that are difficult to formulate, as well as new drug delivery platform technologies. In 2016, EASYWELL BIOMEDICALS acquired Transwell Biotech, Inc., whose technologies focus on regenerative medicine that involves the application of fetal skin cells on wounds.

EASYWELL BIOMEDICALS has a strong R&D that focuses on the production of technically challenging generics and branded products across a wide range of therapeutic classes and dosage forms. EASYWELL BIOMEDICALS is comprised of industrial leaders who are experienced in the design, development, production, marketing, and sales of both medical devices and pharmaceuticals.

EASYWELL BIOMEDICALS continues to develop and integrate medical devices and pharmaceuticals by using scientific approaches, while simultaneously using innovating technologies for better patient compliance, product safety, and efficacy.

EASYWELL BIOMEDICALS is committed to continually elevate and refine the products it delivers to its customers and patients around the globe.